Senescent cells accumulate throughout the body with advanced age, diseases and chronic
conditions. They negatively impact health and function of multiple systems, including the …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy and
new therapeutics are much needed. Profiling patient leukemia drug sensitivities ex vivo, we …

T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of
progenitor T cells. Despite significant improvements in survival of T-ALL/LBL over the past …

Relapse and refractory T-cell acute lymphoblastic leukemia (T-ALL) has a poor prognosis,
and new combination therapies are sorely needed. Here, we used an ex vivo high …

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy,
and there is an unmet need for targeted therapies, especially for patients with relapsed …

LCK is a novel therapeutic target in~ 40% of T-cell acute lymphoblastic leukemia (T-ALL),
and dasatinib and ponatinib can act as LCK inhibitors with therapeutic effects. We herein …

PURPOSE Acute lymphoblastic leukemia (ALL) can occur across all age groups, with a
strikingly higher cure rate in children compared with adults. However, the pharmacological …

CRISPR genome editing approaches theoretically enable researchers to define the function
of each human gene in specific cell types, but challenges remain to efficiently perform …

Acute myeloid leukemia (AML) with co-occurring NUP98-NSD1 and FLT3-ITD is associated
with unfavorable prognosis and represents a particularly challenging treatment group. To …

Summary T‐cell ALL (T‐ALL) is an aggressive malignancy of T‐cell progenitors. Although
survival outcomes in T‐ALL have greatly improved over the past 50 years, relapsed and …